Lloyd Damon

MD

Hematologist
Advocate for personalized medicine

About me

Dr. Lloyd Damon is a hematologist and researcher who specializes in blood cancers such as lymphomas and leukemias.

Damon studies new treatments for acute myeloid and acute lymphoblastic leukemias. In 1995, he was an early investigator of rituximab, the first monoclonal antibody approved to treat human cancer, specifically lymphoma. (Monoclonal antibodies are cancer-fighting molecules produced in the lab and then infused to work with the patient's immune system against cancer.) In 1998, Damon developed a high-dose regimen for mantle cell lymphoma involving autologous stem cell transplants – which use the patient's own stem cells. When studying cytarabine, an important leukemia drug, he discovered the risk factors for an uncommon toxic effect it can have on the brain and then developed a method for modifying the dose that reduces this side effect significantly.

Damon earned his medical degree at the University of Michigan. He completed an internal medicine residency and a fellowship in hematology and oncology at UCSF, where he joined the faculty in 1988. He is deputy chief of the Divisions of Hematology and Medical Oncology.

  • Education

    University of Michigan, 1982

  • Residencies

    UCSF, Internal Medicine, 1985

  • Fellowships

    UCSF, Hematology/Oncology, 1988

  • Board Certifications

    Hematology, American Board of Internal Medicine

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Professor

All blood diseases – malignant or benign – are significant, and I take a personalized approach to every patient.

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

Decorative Caduceus

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Mainten...

The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomiz...

Recruiting

Decorative Caduceus

Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic L...

This is a Phase I/II study of blinatumomab in combination with pembrolizumab in adult patients with relapsed or refractory B-lineage ALL The primary objective of this study is to determine if the addition of pembroli...

Recruiting

Decorative Caduceus

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

This phase Ib trial studies the best dose of gemtuzumab ozogamicin when given together with CPX-351 in treating patients with acute myeloid leukemia that has come back after it was previously in remission. CPX-351 is...

Recruiting

Share